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a  b  s  t  r  a  c  t
Normal  epithelium  exists within  a dynamic  extracellular  matrix  (ECM)  that  is tuned  to  regulate  tissue
speciﬁc  epithelial  cell  function.  As  such,  ECM contributes  to tissue  homeostasis,  differentiation,  and  dis-
ease,  including  cancer.  Though  it is now  recognized  that  the functional  unit  of normal  and  transformed
epithelium  is the epithelial  cell  and  its adjacent  ECM,  we lack  a  basic  understanding  of  tissue-speciﬁc
ECM composition  and  abundance,  as well  as  how  physiologic  changes  in  ECM  impact  cancer  risk  and  out-
comes.  While  traditional  proteomic  techniques  have  advanced  to robustly  identify  ECM  proteins  within
tissues,  methods  to  determine  absolute  abundance  have  lagged.  Here,  with  a  focus  on  tissues  relevant  to
breast cancer,  we utilize  mass  spectrometry  methods  optimized  for absolute  quantitative  ECM  analysis.
Employing  an  extensive  protein  extraction  and  digestion  method,  combined  with  stable  isotope  labeled
Quantitative  conCATamer  (QconCAT)  peptides  that  serve  as  internal  standards  for  absolute  quantiﬁcation
of  protein,  we quantify  98  ECM,  ECM-associated,  and  cellular  proteins  in  a single  analytical  run.  In  rodent
models,  we  applied  this  approach  to  the  primary  site of  breast  cancer,  the  normal  mammary  gland,  as  well
as a  common  and particularly  deadly  site  of breast  cancer  metastasis,  the  liver.  We  ﬁnd that  mammary
gland  and  liver  have  distinct  ECM  abundance  and  relative  composition.  Further,  we show  mammary  gland
ECM abundance  and  relative  compositions  differ  across  the  reproductive  cycle,  with  the  most  dramatic
changes  occurring  during  the  pro-tumorigenic  window  of  weaning-induced  involution.  Combined,  this
work suggests  ECM  candidates  for  investigation  of  breast  cancer  progression  and  metastasis,  particularly
in postpartum  breast  cancers  that  are  characterized  by  high  metastatic  rates.  Finally,  we  suggest  that
with use of absolute  quantitative  ECM  proteomics  to characterize  tissues  of  interest,  it will  be  possible
to  reconstruct  more  relevant  in  vitro  models  to investigate  tumor-ECM  dynamics  at  higher  resolution.
© 2016  The  Authors.  Published  by  Elsevier  Ltd. This  is an  open  access  article  under  the CC  BY-NC-ND
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1. Introduction
Mechanistic studies of rodent mammary gland development
reveal requisite roles for ECM in mammary epithelial cell prolifera-
tion, differentiation, and cell-death decisions (Aggeler et al., 1988;
Streuli et al., 1991; Werb et al., 1996; Fata et al., 2004; Schedin et al.,
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004; Nelson et al., 2006). In fact, pioneering investigations identi-
ed the functional unit of the epithelium as the cell plus its adjacent
CM (Bissell and Barcellos-Hoff, 1987; Barcellos-Hoff et al., 1989).
hese ﬁndings shifted studies aimed at understanding epithelial
ell function from a cell-intrinsic to a cell-stroma focus (Howlett
nd Bissell, 1993). Investigation of the relationship between tissue
CM and epithelium has also been applied to the study of breast
ancer, with important gains (Weigelt et al., 2014).
The functions of matrix proteins in breast cancer have been
ssessed primarily using single, puriﬁed ECM proteins or by
dmixing ECM proteins of interest with commercially available
ngelbreth-Holm Swarm (EHS) matrix that is enriched in laminin-
11 (Shaw et al., 2004; Lee et al., 2007; Fischbach et al., 2007; Krause
t al., 2008). Such studies identiﬁed speciﬁc ECM protein-integrin
nteractions, matrix stiffness, and matrix architecture as critical
ediators of tumor cell function (Schmeichel et al., 1998; DuFort
t al., 2011; Schedin and Keely, 2011; Levental et al., 2009). Single
CM molecules, including collagen I, ﬁbronectin, and tenascin-C,
isplay clear roles in promoting tumor cell proliferation, motility,
nd invasion (Levental et al., 2009; Hancox et al., 2009; Maity et al.,
011; Nguyen-Ngoc et al., 2012; Maller et al., 2013). ECM roles
n breast cancer risk are also suggested, as high mammographic
reast density, indicative of elevated collagen content in the breast,
ncreases epithelial cell transformation by 4–6-fold (Boyd et al.,
998; Li et al., 2005). The relationship between ﬁbrillar collagen
 and cancer incidence and progression have been corroborated in
odent models, where high collagen I content in the murine mam-
ary gland results in a ∼3-fold increase in tumor formation as well
s increased lung metastasis (Provenzano et al., 2008). There is also
vidence that distinct ECM proteins at secondary sites of metasta-
is impact metastatic success (Barkan et al., 2010; Erler et al., 2009;
skarsson et al., 2011; Malanchi et al., 2012; Ghajar et al., 2013;
osta-Silva et al., 2015; Kaplan et al., 2005; Burnier et al., 2011;
oto et al., 2015). In particular, prominent work in the metastasis
eld has shown roles for lung and liver ﬁbronectin in support-
ng disseminated tumor cell seeding and growth in murine models
f colon, mammary, and pancreatic adenocarcinomas (Costa-Silva
t al., 2015; Kaplan et al., 2005). Cumulatively, these studies impli-
ate ECM in all stages of cancer progression, from initiation to
etastatic outgrowth at secondary sites.
The reductionist approach of investigating single ECM protein-
ell interactions in vitro, or manipulating single proteins in vivo,
hile revealing, does not replicate the complex ECM milieu of an
n vivo tissue microenvironment. One example of the importance of
issue-speciﬁc ECM is found in rodent models of postpartum breast
ancer. In these models, whole tissue mammary ECM, as opposed
o a single protein, has been shown to determine metastatic out-
omes (McDaniel et al., 2006). Relevance to women is implicated,
s postpartum breast cancer patients have a ∼3-fold increased
isk for metastasis and death (Callihan et al., 2013; Johansson
t al., 2011; Stensheim et al., 2009), a poor prognosis attributed,
n part, to ECM remodeling during postpartum breast involution
Schedin, 2006). Speciﬁcally, weaning-induced mammary gland
nvolution is characterized by deposition and partial proteolysis
f radially aligned ﬁbrillar collagen, ﬁbronectin, and tenascin-C
McDaniel et al., 2006; Lyons et al., 2011). Further, evidence that
nvolution-speciﬁc mammary ECM promotes metastasis has been
emonstrated in xenograft models. Tumor cells co-injected with
ammary ECM isolated from involuting glands grew larger tumors
ithin the mammary fat pad and metastasized at much higher rate
ompared to tumor cells co-injected with mammary ECM isolated
rom nulliparous rats (McDaniel et al., 2006). These data highlight
he need to better understand how physiologic cues as well as
isease states impact ECM composition and abundance, and pro-
ide compelling rationale for developing improved quantitative
ethodologies for ECM proteomics.chemistry & Cell Biology 81 (2016) 223–232
Robust characterization of tissue-speciﬁc ECM complexity and
abundance has been largely hindered by technical challenges in
the ﬁeld of proteomics. For unbiased biochemical identiﬁcation of
proteins, mass spectrometry provides a highly sensitive approach.
However, improvements to proteomic approaches for the study
of tissue-speciﬁc ECM have been hindered by the proteolytic-
and solubilization-resistant properties of ECM proteins, which are
often high molecular weight, extensively glycosylated, and cova-
lently cross-linked. While signiﬁcant advances in ECM protein
identiﬁcation have occurred recently (Naba et al., 2014a,b; Hansen
et al., 2009; Didangelos et al., 2010), proteomics approaches still
largely fail to adequately quantify many ECM proteins despite their
high abundance in tissues (Hill et al., 2015). We have recently
established methods for improved tissue solubilization and abso-
lute protein quantiﬁcation to interrogate tissue-speciﬁc ECM. This
approach permits quantitative assessment of a subset of ECM pro-
teins that represent >99% of spectra matching to core ECM and
ECM-afﬁliated proteins identiﬁed in mammary gland and liver
by global proteomics (Hill et al., 2015; Baiocchini et al., 2016;
Geiger et al., 2013). To gain insight into primary breast cancer
and site-speciﬁc metastasis, we  utilize our quantitative proteomics
approach to compare rat mammary gland and liver, as the liver
is a common and lethal site of breast cancer metastasis. We  also
investigate ECM composition and abundance changes in the mam-
mary gland across a reproductive cycle. Our objective was to gain
insight into potential roles of ECM in the pro- tumorigenic win-
dow of weaning-induced mammary gland involution. This targeted
ECM proteomics approach is anticipated to facilitate improved in
vivo characterization, and in vitro reconstruction of epithelial cell
microenvironments for use in cancer, stem cell, and regenerative
biology.
2. Materials and methods
2.1. Rodent studies
The OHSU Institutional Animal Care and Use Committees
approved all animal procedures. Sprague-Dawley female rats (Har-
lan), 70 +/−3  days of age, were bred and tissues collected as
described (Schedin et al., 2004; Bemis and Schedin, 2000). Snap
frozen, pulverized lymph node-free mammary gland [n = 5/group
for nulliparous, late pregnancy (day 18–21), lactation, involution
days 2, 4, 6, 8, and 10, and four weeks post-weaning (regressed)]
and gallbladder-free liver [n = 6 for nulliparous] were used for
ECM-based QconCAT proteomic analyses. Pooled samples gener-
ated from the above mentioned biologic replicates were utilized
for global proteomics.
2.2. Imaging
Tissue H&E and trichrome stains were scanned on an Ape-
rio ScanScope AT, image analysis was performed using Aperio
ImageScope software (Leica Biosystems).
2.3. Sample preparation for proteomic analysis
Approximately 5 and 50 mgs  of fresh frozen mammary gland
and liver, respectively, was  pulverized in liquid nitrogen and pro-
cessed as described (Hill et al., 2015). Brieﬂy, tissue samples
were homogenized in CHAPS buffer with 2 mm glass beads using
mechanical agitation (Bullet Blender®, Next Advance) on power 8
for 3 min. Following homogenization, tissue samples were sequen-
tially extracted using high-speed centrifugation after vortexing in
high salt CHAPS buffer, 6 M urea, and CNBr buffers resulting in 3
fractions for each sample: (1) cellular fraction, (2) soluble ECM,
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Fig 1. Quantitative QconCAT ECM proteomics pipeline.
A) Experimental pipeline for quantitative ECM proteomics. Tissues are sequentially extracted to obtain cellular, soluble ECM (sECM), and insoluble ECM (iECM) fractions.
QconCATs are spiked into fractions and samples are then proteolytically digested (full list of Quantitative conCATamers in Supplementary Table 1). B) Table of a subset of
the  98 ECM/ECM-associated proteins represented in the Quantitative conCATamers (QconCAT) used to determine absolute concentration of proteins by mass spectrometry
proteomics; the ﬁrst three amino acids of the peptide represented are identiﬁed in italics (top). Representative chromatographic elution proﬁle of equal molar concentration
of  conCATamer peptides detected by LC-SRM mass spectrometry demonstrates peptide-speciﬁc spectral proﬁles (bottom). For labeled peaks, darker shading indicates 12C6
peptide (endogenous) and lighter shading indicates 13C6 peptide (QconCAT), which is spiked in at known, equimolar concentrations. Integrated peak areas are used for ratio







Sractions of rat mammary gland (left) and liver (right) according to the DAVID gen
ECM, and iECM fractions of rat mammary gland (left) and liver (right). E) Ratio of c
uantiﬁcation in rat mammary gland and liver.
nd (3) insoluble ECM (Figure 1A). All fractions were ran by liq-
id chromatography-tandem mass spectrometry (LC–MS/MS) and
iquid chromatography-selected reaction monitoring (LC-SRM). LC-
RM analysis was done on n = 5 mammary gland/group and n = 6logy functional group classiﬁcation. D) Percent of collagen I identiﬁed in cellular,
n alpha-1(I) to collagen alpha-2(I) for peptide spectral matches vs. QconCAT based
liver samples, with n = 7 technical replicates. LC–MS/MS analysis
was done on pooled biological replicates for an n = 1/group.
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.4. Detergent/chaotrope removal & protein digestion
Sample cleanup and protein digestion was carried out as
escribed (Johnson et al., 2016). QconCAT standards were spiked
nto each sample prior to ﬁlter assisted sample prep (FASP) to yield
alues of 100 fmol 13C6 QconCAT/5 g of protein for LC-SRM injec-
ions. Equal volumes of biological replicates were combined for
C–MS/MS analysis.
.5. Liquid chromatography tandem mass spectrometry & data
nalysis
Samples were analyzed by LC-SRM and LC–MS/MS as described
Johnson et al., 2016). Equal volumes from each post-digestion
ample were combined and injected every third run and used to
onitor technical reproducibility. Skyline was used for method
evelopment and to extract the ratio of endogenous light peptides
o heavy internal standards from LC- SRM data for protein quan-
iﬁcation as described (MacLean et al., 2010). LC–MS/MS data was
rocessed as previously described (Hill et al., 2015). Limits of detec-
ion, quantiﬁcation, and dynamic range were determined for each
eptide as previously described (Hill et al., 2015) and provided in
upplementary Table 1. Principal component analysis (PCA) and
artial least squares discriminate analysis (PLS-DA) were calculated
sing the MetaboAnalyst online platform (Xia et al., 2015).
.6. Statistics
Statistical analysis was performed using GraphPad Prism 6.
omparison of two groups was done by two-sided Student’s T-test.
omparison of >two groups was done using One-way ANOVA.
. Results
.1. Development of quantitative ECM proteomic methodology
To better understand the complexity of epithelial cell-ECM
icroenvironments in vivo, we developed novel extraction and
igestion methods for proteomic characterization of ECM (Hansen
t al., 2009; Hattar et al., 2009; O’Brien et al., 2012). While these
ethodological advancements have furthered our understanding
f ECM composition, they lacked the ability to accurately quantify
CM protein abundance in the microenvironment. To overcome
his barrier, we designed six recombinantly generated Quantita-
ive conCATamers (QconCAT) (Hill et al., 2015; Pratt et al., 2006)
ade of 201 stable isotope labeled (SIL) peptides representing
8 ECM, ECM-associated, and common cellular proteins (Supple-
entary Table 1). Peptides speciﬁc to intracellular proteins from
ifferent subcellular locations were included to serve as a qual-
ty control measure for development of tissue extraction methods
nd as a relative measure of cellularity. These reporter peptides are
hen ‘spiked into’ experimental protein lysates at equimolar con-
entrations to serve as internal quantitation controls. Fig. 1A shows
 schematic representation of the tissue extraction/fractionation,
nd digestion workﬂows used prior to LC-SRM data acquisition.
ur fractionation protocol yields three distinct fractions, cellular,
oluble ECM (sECM), and insoluble ECM (iECM). The iECM fraction
s then treated with cyanogen bromide (CNBr) to increase solubil-
ty. Reporter ECM peptides are added to all fractions, and samples
re proteolytically digested and run by LC-SRM. The consolidated
esults from the three fractions yield total quantity for a given
rotein within a tissue. This targeted mass spectrometry method
llows us to measure all 201 SIL QconCAT peptides and endogenous
nalogs in a single 30 min  analytical run. Molecular heterogeneity
an differentially affect signal intensity during LC-SRM data acqui-
ition, which is why the inclusion of internal standardized controlschemistry & Cell Biology 81 (2016) 223–232
for each unique protein of interest is essential for determining
accurate absolute concentrations. We  ﬁnd the QconCAT generated
heavy peptides allow for precise quantiﬁcation, as the reporter pep-
tides behave identically to the endogenous peptides in terms of
mass spectrometry fragmentation and ionization, chromatographic
separation, and enzymatic digestion efﬁciency (Fig. 1B).
To conﬁrm increased detection of rat mammary and liver ECM
proteins with this method, the protein identiﬁcations within the 3
fractions (cellular, sECM, and iECM) were grouped into functional
classiﬁcations of cytoskeletal, other cellular, matricellular, and sev-
eral ECM categories, using gene ontology terminology from the
Database for Annotation, Visualization, and Integrated Discovery
(DAVID) (Dennis et al., 2003). The vast majority of mammary cel-
lular proteins fractionate with CHAPS detergent into the cellular
fraction, whereas sECM and iECM fractions were highly enriched
for ECM proteins (Fig. 1C). In the rat liver, we  again found that
the majority of cellular proteins resolved with CHAPS. The liver
sECM fraction was  enriched for matricellular proteins and the
iECM fraction further enriched for ﬁbrillar collagens (Fig. 1C). Strik-
ingly, 52% of mammary and 83% of liver collagen I was detected
in the iECM fraction after CNBr treatment (Fig. 1D), a fraction not
routinely incorporated into traditional proteomic methods. Addi-
tionally, other residual ECM proteins failed to completely solubilize
with urea (sECM fraction), highlighting the importance of CNBr sol-
ubilization and analysis of the iECM fraction (Fig. 1C). The utility of
using our targeted reporter peptide approach compared to a global
proteomics approach is further realized by analyzing the ratio of
collagen alpha-1(I) to collagen alpha-2(I) by LC-SRM. The expected
stoichiometry between these two chains is 2:1 (COL1A1/COL1A2),
based on the assembly of ﬁbrillar collagen triple helices containing
two alpha-1 chains and one alpha-2 chain. We  ﬁnd that the targeted
approach with QconCATs more accurately reﬂects the theoretical
ratio of 2:1 than a traditional global proteomics approach (Fig. 1E).
3.2. QconCAT based proteomics reveals unique and shared
mammary gland and liver ECM proﬁles
A major rate-limiting step of metastatic success has been
attributed to discordance between the ECM requirements of the
seeding tumor cell and the ECM microenvironment at the sec-
ondary site (Barkan et al., 2010; Oskarsson et al., 2011; Malanchi
et al., 2012; Costa-Silva et al., 2015; Luzzi et al., 1998). In the con-
text of breast cancer, we utilized our quantitative ECM proteomics
to begin to address this hypothesis by elucidating tissue-speciﬁc
differences as well as similarities between the primary and liver
metastatic site in the nulliparous female adult rat. We  focused on
the liver, as one of three common sites of breast cancer metas-
tasis (Berman et al., 2013; Savci-Heijink et al., 2015; Harrell et al.,
2012), which confers the worst prognosis (Wyld et al., 2003; Tarhan
et al., 2013; Tseng et al., 2013). The resulting proteomic data were
grouped into 10 functional classiﬁcations of proteins including:
basement membrane, ECM regulator, ﬁbril-associated collagens
with interrupted triple helices (FACIT) collagen, ﬁbrillar collagen,
matricellular, other ECM, secreted ECM, and structural ECM, using
DAVID, as described in Fig. 1 (Dennis et al., 2003). This analysis
demonstrated an abundance of ﬁbrillar collagens and matricellular
proteins in mammary tissue, and high levels of cytoskeletal and
other cellular proteins in liver (Fig. 2A, Supplementary Tables 2
and 3), data consistent with the high stromal and low epithelial
content in the mammary gland as compared to the liver (Fig. 2B).
Further, these tissues differed markedly in overall ECM abundance,
with ∼100 nmol of ECM per gram of tissue in the mammary gland
compared to ∼8.5 nmol/g in the liver (Fig. 2C).
To further interrogate ECM complexity and abundance of ECM
proteins between the mammary gland and the liver, we  removed
cellular proteins from the assessment. This ECM- biased analysis
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Fig. 2. QconCAT based ECM proteomics reveals unique mammary gland and liver ECM proﬁles.
A)  QconCAT based ECM proteomics of nulliparous rat mammary gland and liver tissues displayed as total abundance of proteins (nmol/g of tissue) grouped by DAVID gene
ontology functional classiﬁcations; n = 5 rats/group for mammary gland and n = 6 rats for liver analyses. B) Representative H&E stained rat mammary gland (MG; left) and
liver  (right) showing tissue speciﬁc differences in stromal-epithelial cell composition; scale bar = 60 m (arrow = MG  epithelium; liver H&E shows epithelium throughout the
tissue).  C) Nanomolar concentration of total ECM per gram of tissue from QconCAT proteomics in the mammary gland and liver. D) Abundance of ECM and ECM-associated
proteins based on DAVID gene ontology functional groups with cytoskeletal and cellular protein groups excluded. E) Twenty most abundant ECM proteins in the rat MG
(left)  and liver (right) as detected by QconCAT proteomics. Tabular results in Supplementary Tables 2 & 3. F) Nanomolar concentration of ﬁbrillar collagen in MG and liver
f ﬁcatio









Erom  QconCAT proteomic analysis (top left) and collagen trichrome staining quanti
f  rat MG  (bottom left) and liver (bottom right); scale bar = 250 m,  inset scale bar
xcluding collagen I, in the rat MG (left) and liver (right) as detected by QconCAT pr
evealed that nulliparous mammary gland ECM is >80% ﬁbrillar
ollagen, ∼9% matricellular proteins, 1.3% basement membrane
roteins, and ∼5% combined FACIT collagens and structural, reg-
latory, secreted and other ECMs (Fig. 2D). In contrast, in the liver,
atricellular proteins make up 44% of ECM proteins, followed by
6.4% ﬁbrillar collagen, ∼10% basement membrane, and 15.3% com-
ined FACIT collagens and structural, regulatory, secreted and other
CMs (Fig. 2D). Although the absolute concentration of ﬁbrillarn in MG  and liver (top right). Representative trichrome stained images (blue stain)
m.  * = p-value < 0.0001, Student’s T-test. G) Twenty most abundant ECM proteins,
ics, tabular results shown in Supplementary Tables 2 & 3.
collagen is vastly different between mammary gland and liver, ﬁb-
rillar collagen I remains the most abundant single ECM protein in
both tissues (Fig. 2E), providing further support for an essential
role of collagen I in tissue structure and homeostasis (Mouw et al.,
2014). Our observed molar concentrations of ﬁbrillar collagens in
mammary gland and liver (Fig. 2F, upper left panel) correlate with
relative ﬁbrillar collagen abundance detected by trichrome stain






























































Fig. 3. Quantitative ECM proteomics reveals dynamic and cyclical mammary gland
ECM remodeling across the reproductive cycle.
Principle component analysis of quantitative ECM proteomics performed
on rat mammary glands across the reproductive cycle (Nullip = nulliparous;
Preg = pregnancy days 18–21; Lac = lactation day 10; InvD2-InvD10 = involution days28 E.T. Goddard et al. / The International Journal
Fig. 2F, upper right panel and representative images), reinforcing
otential biologic relevance of the QconCAT method.
To investigate ECM complexity beyond ﬁbrillar collagen I, we
tratiﬁed QconCAT data based on the next twenty most abundant
CM proteins (Fig. 2G, highlighted in Supplementary Tables 2 and
). Despite the concentration of ECM in the mammary gland drop-
ing signiﬁcantly with removal of collagen I, ECM concentration
f the remaining twenty proteins was still ∼4-fold higher in the
ammary gland compared to liver (Fig. 2E, G). Overall, we  iden-
iﬁed the same ECM proteins in both the mammary gland and
iver, however, their relative ratios were tissue speciﬁc (Fig. 2G).
or example, lumican, collagen VI, and collagen XIV were preva-
ent in the mammary gland and collagen VI and ﬁbronectin were
revalent in liver (Fig. 2G). Further, we ﬁnd that while ﬁbronectin is
resent at ∼equimolar concentrations in the mammary gland and
iver (Supplementary Fig. 1), it makes up only 0.64% of total ECM
oncentration in the mammary gland compared to 4.74% in the liver
Fig. 2G, Supplementary Tables 2 & 3). The absolute quantitation
ethod also permits the identiﬁcation of a subset of ECM proteins,
ncluding thrombospondin 1 and ﬁbulin 4, that are present at sig-
iﬁcantly higher concentrations in liver, in spite of the mammary
land having ∼12-fold higher concentration of total ECM (Supple-
entary Fig. 1). In sum, these analyses demonstrate the ability of
he QconCAT method to provide absolute molar concentrations of
peciﬁc ECM proteins within the mammary gland and liver and
dentify tissue-speciﬁc ECM complexity.
.3. Mammary gland ECM proteomics across the reproductive
ycle
The microenvironment of the mammary gland can be neu-
ral, tumor- promotional, or tumor-suppressive, dependent upon
eproductive state (Maller et al., 2013; Martinson et al., 2014),
 phenomenon thought to be driven in large part by reproduc-
ive state-dependent changes to mammary ECM (Maller et al.,
013; Schedin et al., 2004; Lyons et al., 2011). Speciﬁcally, in
odent models of breast cancer, mammary tumor cells grow most
obustly in the weaning-induced involuting microenvironment,
oderately in the nulliparous mammary microenvironment, and
east when transplanted into parous mice, whose mammary glands
ave completed weaning-induced involution (Maller et al., 2013;
artinson et al., 2014). Despite this dynamic ﬂuctuation in tumor-
upportive function, mammary ECM has never been assessed across
he reproductive cycle using quantitative proteomics. To this end,
e analyzed rat mammary ECM in whole gland lysates from nulli-
arous, pregnancy, lactating, involuting (i.e., 2, 4, 6, 8 and 10 days
ost-weaning), and fully involuted (regressed) stages. Principle
omponent analysis (PCA) on LC-SRM data generated from these
CM proteomics data revealed a cycle of mammary gland ECM
emodeling across pregnancy, lactation and involution, upon which
he gland ultimately returns to an ECM microenvironment similar
o, but distinct from, the nulliparous state (Fig. 3 & Supplemen-
ary Fig. 2). We observed a >2-fold drop in ECM abundance when
omparing nulliparous to pregnancy, lactation, and involution day
 stages (Fig. 4A), data consistent with the increased epithelial cel-
ularity as well as loss of collagen staining at these reproductive
tages (Schedin et al., 2004). Total ECM abundance increased to
re-pregnant levels by involution day 6, consistent with epithe-
ial cell loss and stromal repopulation upon weaning (Lund et al.,
996). We  also observed increased abundance of ECM in the fully
egressed mammary gland compared to the nulliparous host, data
uggestive of unique mammary microenvironments in nulliparous
nd parous hosts (Fig. 4A), and consistent with previous reports
Maller et al., 2013).
We next compared the top twenty most abundant ECM proteins
n the mammary glands from nulliparous, involution days 2 and 6,2, 4, 6, 8, and 10; Reg = regressed, 4 weeks post- weaning); n = 5 rats/grp. Data
shows that ECM composition in the mammary gland changes in phase with the
reproductive cycle in a stepwise, cyclical fashion.
and regressed stages, since these stages have differential tumor-
promotional attributes (Maller et al., 2013; Martinson et al., 2014).
We conﬁrmed that collagen I is the predominant ECM protein in
the gland (Hansen et al., 2009; O’Brien et al., 2012), and extended
these analyses to demonstrate that collagen abundance is dramat-
ically reduced during pregnancy, and does not return to high levels
until 6 days post-weaning (Fig. 4A and B). To investigate ECM com-
plexity further, we removed collagen I from the analysis and found
a high abundance of lumican, collagen VI, and collagen XIV in the
nulliparous and regressed rat mammary gland (Fig. 4C and D &
Supplementary Table 2). In contrast to these relatively quiescent
mammary glands, actively involuting glands exhibited a prominent
abundance of collagen VI, thrombospondin 1, and galectin-3 (Fig. 4C
and D). Two  additional ECM proteins not found in the top twenty
list, tenascin-C and collagen XII, also increased in abundance during
mammary gland involution (Fig. 4D). Intriguingly, the ECM com-
position of the involuting mammary gland somewhat resembles
that of the liver, which share increased collagen VI and ﬁbronectin,
and reduced lumican and collagen I abundances (Fig. 2G and C).
Principle component analysis conﬁrmed tissue speciﬁcity of liver
and mammary ECM, but also revealed that liver ECM resembles the
mammary gland at pregnancy, lactation, and involution days 2 and
4, compared to other reproductive stages (Supplementary Fig. 3).
Taken together, these data highlight how quantitative ECM pro-
teomics can provide prime candidates for the investigation of the
roles of ECM in breast cancer progression.
4. DiscussionThis work describes advances made in sample preparation tech-
niques and quantitative proteomics methods for the study of tissue
ECM composition and abundance. Using this experimental pipeline,
we characterized tissue-speciﬁc ECM composition of the rodent
E.T. Goddard et al. / The International Journal of Biochemistry & Cell Biology 81 (2016) 223–232 229
Fig. 4. Quantitative ECM proteomics unravels the unique composition and abundance of ECM proteins across the reproductive cycle.
QconCAT based ECM proteomics of rat MG tissues across the reproductive cycle, with identiﬁed cellular protein groups removed; n = 5 rats/grp. B) Twenty most abundant ECM











lnd  Reg stage rat MG,  with collagen I removed from the analysis. Tabular results in
collagen VI, thrombospondin 1, galectin-3, tenascin-C) ECM protein levels, as well 
ullip,  InvD2, InvD6, and Reg stages, n = 5 rats/grp; * = p-value < 0.05, ** = p-value < 0
ammary gland and liver, a lethal site of breast cancer metastasis,
o a level not previously accomplished. These analyses identiﬁed
utative tissue-speciﬁc ECM components, including lumican and
ollagen XIV, which were prevalent in the mammary gland, and
bronectin which was prevalent in the liver. We  also found shared
CM components between these two tissues, including abundant
roteins such as collagen types I and VI, as well as less abundant col-
agen types IV and V. We  also show that the abundance of mammarylementary Table 2. D) Select tumor suppressive (lumican) and tumor- promotional
agen XII from individual rats, as determined by QconCAT based ECM proteomics of
** = p-value < 0.001, **** = p-value < 0.0001, One-way ANOVA.
gland ECM is altered across the reproductive cycle, building upon
previous studies that have identiﬁed major shifts in mammary
ECM with pregnancy, lactation, involution, and regression (Schedin
et al., 2004; Lyons et al., 2011; Bemis and Schedin, 2000; O’Brien
et al., 2010). In particular, we  see elevated abundance of known
pro- tumorigenic ECM proteins collagen VI, thrombospondin 1,
galectin-3, and tenascin-C during weaning- induced mammary
gland involution. Further, to the best of our knowledge, we iden-
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ify collagen XII for the ﬁrst time as elevated during post-weaning
ammary involution. Importantly, potential roles for each of these
ighlighted ECM proteins in breast cancer metastasis have been
lucidated, with the exception of collagen XII (Iyengar et al., 2005;
oachim et al., 2002; Yee et al., 2009; Zhang et al., 2014). While col-
agen XII has been shown to be upregulated in malignant breast
ancer cell lines, and has been identiﬁed as a prognostic marker
n other cancers, its role in breast cancer progression has yet to be
stablished (Karagiannis et al., 2012; Yen et al., 2014). In sum, our
ata demonstrate tissue-speciﬁc ECM complexity and ECM protein
toichiometry between the mammary gland and liver, and across
 reproductive cycle within the mammary gland, data consistent
ith ECM contributing to differential tissue function.
Somewhat surprisingly, we also found that the ECM proﬁle of the
arly involuting mammary gland (InvD2-InvD4) resembled that of
he liver. This ﬁnding may  provide insight into site-speciﬁc metas-
asis of postpartum breast cancers, as disseminated tumor cells may
xperience a survival advantage if primary and secondary sites have
imilar ECM compositions post- weaning. A prediction of these data
re increased risk for liver metastasis in postpartum breast cancer
atients; a relationship that remains unexplored. Of potential rele-
ance, risk for liver metastasis is elevated in younger breast cancer
atients (Cummings et al., 2014), a signiﬁcant proportion of whom
re likely to be postpartum breast cancer patients (Callihan et al.,
013).
Our quantitative QconCAT ECM proteomics approach facili-
ates in-depth characterization of tissue-speciﬁc ECM abundance
nd composition at a level not previously attained. The advances
e report result, in part, from improved solubilization using a
NBr extraction step that permits detection of historically insol-
ble ECM proteins such as collagen I. Further, the use of in-
ouse generated QconCATs for quantiﬁcation of tissue ECM pro-
eins has several advantages over traditional relative quantitative
pproaches, including 1) SIL peptide mimics that control for matrix
ffects during proteomic acquisition, allowing for direct compar-
son between heterogeneous tissues, 2) inclusion of full-length
conCATs during digestion, which control for sample loss and
igestion variability, and 3) absolute quantitative values allowing
or inter-protein and -experiment comparisons between samples.
owever, as with any ﬁrst-generation experimental pipeline, there
re limitations to the methodology that need to be addressed in
uture work. First, targeted proteomics is inherently more speciﬁc
nd therefore will only quantitate peptides/proteins included in
he QconCAT library. However, when comparing our current Qcon-
AT library coverage to samples simultaneously run using global
roteomics, only an additional 7 and 8 ECM proteins (primarily
nnexins, accounting for 0.43% and 0.11% of total spectral matches)
ere identiﬁed that were not covered by the QconCAT library.
urther, QconCAT proteomics quantiﬁed 34 and 41 proteins or pro-
ein isoforms in the mammary gland and liver, respectively, not
dentiﬁed by global proteomics (Supplementary Table 4). These
omparisons highlight the beneﬁts of increased sensitivity when
pplying a targeted proteomics approach, as this level of detec-
ion often requires deep fractionation and multiple runs to achieve
imilar depth using global proteomics.
An additional caveat to QconCAT proteomics is that quantiﬁca-
ion of endogenous peptides with post-translational modiﬁcations
PTMs) is not currently possible. We  circumvent this problem by
esigning QconCAT peptides speciﬁc to proteins that either have
o known PTMs or do not contain a common PTM motif so that
he quantiﬁed endogenous peptide has a higher probability of
epresenting the molar equivalent of the protein it represents. Fur-
hermore, we attempt to include multiple peptides per protein of
nterest to account for splice variants, known PTMs, and matricryp-
ic sites, however a subset of proteins are currently covered by only
 single peptide. Future generations of this QconCAT library willchemistry & Cell Biology 81 (2016) 223–232
increase conﬁdence in protein quantiﬁcation by expanding cover-
age of ECM, ECM-modifying, and ECM-associated proteins, as well
as adding additional peptides for all ECM protein targets. Impor-
tantly, the increased depth of ECM coverage that will be gained
by design of additional QconCATs will ultimately facilitate more
reﬁned characterization of ECM abundance and composition in tis-
sues.
Multiple studies have characterized both the mammary gland
and liver in a variety of normal and tumorigenic contexts (Naba
et al., 2014a, 2014b; Baiocchini et al., 2016; Geiger et al., 2013; Lai
et al., 2008, 2011; Da Costa et al., 2015; Moreira et al., 2010). How-
ever, because these semi-quantitative approaches provide relative,
and not absolute abundance of proteins, it is difﬁcult to compare
data across studies. For example, comparison of collagen cover-
age in the liver across our platform and ﬁve published datasets
revealed marked variability between both identiﬁcation and quan-
tiﬁcation of collagen (Supplementary Table 5). While the majority
of datasets identiﬁed the abundant collagens I & VI, they varied dra-
matically in estimated abundance and in the identiﬁcation of less
abundant collagens. Signiﬁcant differences in estimated abundance
of collagen I between studies are likely derived from variability
in enrichment strategies, and the non-uniform analysis of insolu-
ble collagens in the iECM pellet, a protein fraction not routinely
captured in standard proteomics pipelines (Hill et al., 2015). The
quantitative advantage of QconCATs is apparent with comparison
of collagen alpha-1(I) to collagen alpha-2(I) ratios, as our targeted
approach recapitulated the expected 2:1 ratio (Fig. 1E & Supple-
mentary Table 5). Additionally, collagen alpha- 1/2/3(VI) organizes
into a 1:1:1 heterotrimer (Chu et al., 1990), and again, our study
is the only one to reveal such a distribution (Supplementary Table
5). The level of variability across proteomics datasets highlights the
need for standardization, and suggest that solubilization with CNBr
along with absolute quantiﬁcation may  provide additional biolog-
ical relevance to proteomics pipelines focused on ECM proteins.
To the best of our knowledge, our ECM-based QconCAT pro-
teomics pipeline has provided the most quantitative assessment of
ECM proteins and tissue composition in mammary gland and liver
to date. In the future, the application of this method can be utilized
to more fully interrogate breast cancer progression. For example,
a comparison of young women’s breast tumors and paired metas-
tases, similar to work done by Naba et al. in colorectal cancer (Naba
et al., 2014a), is predicted to reveal widespread ECM differences
and further inform our understanding of breast cancer metastasis.
Further, studies to understand liver, as well as lung, bone, and brain
ECM throughout the reproductive cycle may  shed insight into site-
speciﬁc metastasis in premenopausal breast cancer patients. The
impact of the ECM biased proteomic pipeline could be further real-
ized in the context of regenerative medicine, where understanding
the composition of ECM components and the relative stoichiometry
within speciﬁc organs would be critical steps in accurately reca-
pitulating endogenous matrices. Ultimately, compilation of similar
datasets for additional organs would lay the foundation for an ECM
Atlas that would be capable of comparing absolute quantitative
measurements between all organs, facilitating a broader under-
standing of the role of ECM in physiology and pathology.
5. Conclusions
ECM can be quantitatively analyzed from tissues under diverse
physiologic and pathologic conditions using the improved solu-
bilization and quantitative proteomics methodologies presented
here. We  report tissue-speciﬁc ECM signatures in rat liver com-
pared to mammary gland, as well as diverse ECM complexity and
abundance in the rat mammary gland throughout a reproductive
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mpacts breast cancer progression, particularly postpartum breast
ancer. Our quantitative ECM proteomics approach has broad appli-
ability and can be utilized in studies pertaining to various tissue
nd disease sites, treatment responses, stem cell biology, and tissue
egeneration.
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